Carfilzomib Could Be More Effective In Treating Relapsed Multiple Myeloma
Following after the success of its phase III finding, it was with great pride that Amgen, a multinational biopharmaceutical company, has recently announced that its drug named Carfilzomib or sometimes referred to as Kyprolis plus dexamethasone has allegedly improved the overall survival (OS) in patients with relapsed or refractory multiple myeloma by up to 21 percent as compared to its close competitor dexamethasone plus bortezomib or Velcade. The researchers of study has claimed that the findings have reportedly met the key secondary endpoint of OS, which has also shown that for patients with relapsed or refractory multiple myeloma treated with Carfilzomib and dexamethasone (Kd) has managed to have lived for 7.6 months. The safety data, which will be fully presented at the 16th International Myeloma Workshop, which is being held in New Delhi from March 1 to 4, 2017, were consistent with previously reported study outcomes.
Carfilzomib And Its Properties
In one of his statements reported by ONC Live, Meletios A. Dimopoulos, MD, professor of Clinical Therapeutics at the National and Kapodistrian University of Athens, School of Medicine, who also happens to be the study's co-author has claimed that for an incurable disease like multiple myeloma, a major treatment goal for oncologists and hematologists is to help patients live as long as possible. Based on these data, Prof. Dimopoulos said that the team now knows that Kyprolis does not only have the ability to significantly extend the progression-free survival (PFS) as compared to Velcade, but also the overall survival chances. The researchers have also noted that the finding makes it a clinically meaningful advance in the treatment of relapsed or refractory multiple myeloma.
Furthermore, according to Yahoo, Sean E. Harper, M.D., executive vice president of Research and Development at Amgen has revealed that the results serve as an affirmation of the superiority of Kyprolis over Velcade in relapsed or refractory multiple myeloma patients. Additionally, Harper said that they were the only team to study and demonstrate a survival benefit in a head-to-head comparison with a current standard of care regimen which has also been supported by Kyprolis as a foundational therapy in this patient population. For the study, it was found that the trial has allegedly been designed for patients aged 18 years and older with adenocarcinoma of the pancreas whose disease has progressed after first-line gemcitabine therapy.
The Downside Of Carfilzomib
Meanwhile, experts have highly emphasized that adverse events observed in this updated analysis were consistent with those previously reported for the study dubbed as ENDEAVOR. The most common adverse events in the Kyprolis arm were anemia, diarrhea, pyrexia, dyspnea, fatigue, hypertension, cough, insomnia, upper respiratory tract infection, peripheral edema, nausea, bronchitis, asthenia, back pain, thrombocytopenia and headache. Ultimately, it was found that the primary endpoint of the study is overall survival (OS), while the secondary endpoints are progression-free survival and overall response rate.
HIV News: Woman’s Reproductive Tract Might Hold The Key For The Disease
What is this protein that’s allegedly found in a woman’s reproductive tract that might hold the key to answer the problem in HIV? Considering the continuous efforts to eradicate one of the world’s long dreaded diseases, could Geelong scientists finally shed the light to HIV? Find out what experts have to say
Debunking The Duchenne Muscular Dystrophy: Can Exonics’ CRISPR Be The Answer?
What is Duchenne muscular dystrophy and what causes this genetic disorder? Considering the numerous biotech companies venturing in various cure for diseases nowadays, could their CRISPR therapy put an end to this ongoing problem? Will it be the advent of the disease’s cure? Find out what health experts have to say
Merck & Co.'s Letermovir Offers New Hope For CMV Infections
What is cytomegalovirus? Considering cytomegalovirus is on the rise, how did Merck & Co's so-called positive Phase III data from its Letermovir shed light in fighting the said herpes virus? What's the truth behind claims that Merck has finally found the solution to CMV infections? Find out what health authorities have to say.
MORE IN ITECHPOST
List of the Best Resources for Students: Study Anything Online
We live in a world full of new opportunities, and more and more people join the internet community in order to study what they are interested in. If you are willing to become better at topics you study in school, university, or just by yourself.
How Do Personal Emergency Response Systems Work?
Personal emergency response systems, known as PERS for short, are systems that help people to raise the alarm and get immediate help when a medical or personal emergency occurs. They are ideal for older people and anyone with a mobility issue or an injury or illness that can cause falls.
How to Download Free Android Emulator for Gaming on PC?
Are you looking to play Android games on PC with the help of the best Android emulator? There are numerous types of online platform which provide user friendly access and support for the interested communities to get immediate access to install their best recommended Android applications.
Learn About Some of the Most Popular Hobbies
We all need our downtime. It helps us recuperate, calm down and manage stress. However, if you want to use your spare time constructively, it is important to decide on what. You may need to look around for something relaxing to help you forget the worries of the world. From stamp collecting and reading to piano playing and camping, here are some of the most popular hobbies in the world to try.